MediCA klinika has acquired Lieporiu Seimos Gydytoju Centras
MediCA klinika, the largest private clinics chain in Lithuania, has acquired Lieporiu Seimos Gydytoju Centras, a private primary care clinic in Siauliai city.
MediCA klinika operates 31 clinics in 16 cities, with revenues of approximately US$35 million. It belongs to CGP Management, a privately owned holding company which also owns the leading pharmacy chain in Lithuania. This acquisition will allow MediCA klinika to expand its market coverage in the country.
Lieporiu Seimos Gydytoju Centra is the largest private clinic in Siauliai city, the fourth largest city of Lithuania, with over 5,000 registered patients.
Oaklins’ team in Lithuania acted as advisor for the buyer throughout the acquisition process, from searching for add-on acquisition targets in Lithuania until final completion.
Talk to the deal team
Related deals
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Learn more